Literature DB >> 29622658

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Barbara Mora1, Toni Giorgino2, Paola Guglielmelli3, Elisa Rumi4, Margherita Maffioli1, Alessandro Rambaldi5, Marianna Caramella6, Rami Komrokji7, Jason Gotlib8, Jean Jacques Kiladjian9, Francisco Cervantes10, Timothy Devos11, Francesca Palandri12, Valerio De Stefano13, Marco Ruggeri14, Richard T Silver15, Giulia Benevolo16, Francesco Albano17, Chiara Cavalloni4, Daniela Barraco1, Michele Merli1, Daniela Pietra4, Rosario Casalone18, Tiziano Barbui19, Giada Rotunno3, Mario Cazzola4, Alessandro Maria Vannucchi3, Francesco Passamonti20.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29622658      PMCID： PMC6119135          DOI： 10.3324/haematol.2017.185751

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Driver mutations' effect in secondary myelofibrosis: an international multicenter study based on 781 patients.

Authors:  F Passamonti; B Mora; T Giorgino; P Guglielmelli; M Cazzola; M Maffioli; A Rambaldi; M Caramella; R Komrokji; J Gotlib; J J Kiladjian; F Cervantes; T Devos; F Palandri; V De Stefano; M Ruggeri; R Silver; G Benevolo; F Albano; D Caramazza; E Rumi; M Merli; D Pietra; R Casalone; T Barbui; L Pieri; A M Vannucchi
Journal:  Leukemia       Date:  2016-11-25       Impact factor: 11.528

2.  Leukemic transformation of polycythemia vera: a single center study of 23 patients.

Authors:  Francesco Passamonti; Elisa Rumi; Luca Arcaini; Carlo Castagnola; Monia Lunghi; Paolo Bernasconi; Matteo Giovanni Della Porta; Nora Columbo; Cristiana Pascutto; Mario Cazzola; Mario Lazzarino
Journal:  Cancer       Date:  2005-09-01       Impact factor: 6.860

3.  Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.

Authors:  Tiziano Barbui; Jürgen Thiele; Francesco Passamonti; Elisa Rumi; Emanuela Boveri; Maria Luigia Randi; Irene Bertozzi; Filippo Marino; Alessandro M Vannucchi; Lisa Pieri; Giada Rotunno; Heinz Gisslinger; Bettina Gisslinger; Leonhard Müllauer; Guido Finazzi; Alessandra Carobbio; Andrea Gianatti; Marco Ruggeri; Ilaria Nichele; Emanuele D'Amore; Alessandro Rambaldi; Ayalew Tefferi
Journal:  Blood       Date:  2012-01-13       Impact factor: 22.113

4.  A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients.

Authors:  Emnet Wassie; Christy Finke; Naseema Gangat; Terra L Lasho; Animesh Pardanani; Curtis A Hanson; Rhett P Ketterling; Ayalew Tefferi
Journal:  Br J Haematol       Date:  2014-12-17       Impact factor: 6.998

5.  Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.

Authors:  Lucia Masarova; Prithviraj Bose; Naval Daver; Naveen Pemmaraju; Kate J Newberry; Taghi Manshouri; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2017-06-02       Impact factor: 3.156

Review 6.  Update from the latest WHO classification of MPNs: a user's manual.

Authors:  Francesco Passamonti; Margherita Maffioli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

7.  Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance.

Authors:  Naseema Gangat; Ayalew Tefferi; Gita Thanarajasingam; Mrinal Patnaik; Susan Schwager; Rhett Ketterling; Alexandra P Wolanskyj
Journal:  Eur J Haematol       Date:  2009-02-19       Impact factor: 2.997

8.  A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

Authors:  F Passamonti; T Giorgino; B Mora; P Guglielmelli; E Rumi; M Maffioli; A Rambaldi; M Caramella; R Komrokji; J Gotlib; J J Kiladjian; F Cervantes; T Devos; F Palandri; V De Stefano; M Ruggeri; R T Silver; G Benevolo; F Albano; D Caramazza; M Merli; D Pietra; R Casalone; G Rotunno; T Barbui; M Cazzola; A M Vannucchi
Journal:  Leukemia       Date:  2017-05-31       Impact factor: 11.528

9.  Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

Authors:  G Barosi; R A Mesa; J Thiele; F Cervantes; P J Campbell; S Verstovsek; B Dupriez; R L Levine; F Passamonti; J Gotlib; J T Reilly; A M Vannucchi; C A Hanson; L A Solberg; A Orazi; A Tefferi
Journal:  Leukemia       Date:  2007-08-30       Impact factor: 11.528

10.  Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera.

Authors:  Guilin Tang; Juliana E Hidalgo Lopez; Sa A Wang; Shimin Hu; Junsheng Ma; Sherry Pierce; Wenli Zuo; Adrian Alejandro Carballo-Zarate; C Cameron Yin; Zhenya Tang; Shaoying Li; L Jeffrey Medeiros; Srdan Verstovsek; Carlos E Bueso-Ramos
Journal:  Haematologica       Date:  2017-05-04       Impact factor: 9.941
View more
  8 in total

1.  Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.

Authors:  Barbara Mora; Paola Guglielmelli; Andrew Kuykendall; Elisa Rumi; Margherita Maffioli; Francesca Palandri; Valerio De Stefano; Marianna Caramella; Silvia Salmoiraghi; Jean-Jacques Kiladjian; Jason Gotlib; Alessandra Iurlo; Francisco Cervantes; Marco Ruggeri; Richard T Silver; Francesco Albano; Giulia Benevolo; David M Ross; Matteo G Della Porta; Timothy Devos; Giada Rotunno; Rami S Komrokji; Ilaria C Casetti; Michele Merli; Marco Brociner; Domenica Caramazza; Giuseppe Auteri; Tiziano Barbui; Daniele Cattaneo; Lorenza Bertù; Luca Arcaini; Alessandro M Vannucchi; Francesco Passamonti
Journal:  Leukemia       Date:  2022-08-30       Impact factor: 12.883

2.  Beyond Hemoglobin: When and How to Work Up Possible Polycythemia Vera.

Authors:  Gene Shaw; Richard Berg
Journal:  Clin Med Res       Date:  2019-10-03

Review 3.  Standard care and investigational drugs in the treatment of myelofibrosis.

Authors:  Daniela Barraco; Margherita Maffioli; Francesco Passamonti
Journal:  Drugs Context       Date:  2019-09-26

Review 4.  Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation.

Authors:  Florian Perner; Caroline Perner; Thomas Ernst; Florian H Heidel
Journal:  Cells       Date:  2019-08-08       Impact factor: 6.600

Review 5.  Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.

Authors:  Barbara Mora; Francesco Passamonti
Journal:  Curr Hematol Malig Rep       Date:  2022-09-01       Impact factor: 4.213

Review 6.  Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.

Authors:  Ruth Stuckey; María Teresa Gómez-Casares
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

7.  Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.

Authors:  Daniela Barraco; Barbara Mora; Paola Guglielmelli; Elisa Rumi; Margherita Maffioli; Alessandro Rambaldi; Marianna Caramella; Rami Komrokji; Jason Gotlib; Jean Jacques Kiladjian; Francisco Cervantes; Timothy Devos; Francesca Palandri; Valerio De Stefano; Marco Ruggeri; Richard T Silver; Giulia Benevolo; Francesco Albano; Michele Merli; Daniela Pietra; Tiziano Barbui; Giada Rotunno; Mario Cazzola; Toni Giorgino; Alessandro Maria Vannucchi; Francesco Passamonti
Journal:  Blood Cancer J       Date:  2018-09-21       Impact factor: 11.037

Review 8.  Is there a gender effect in polycythemia vera?

Authors:  Francesca Palandri; Barbara Mora; Naseema Gangat; Lucia Catani
Journal:  Ann Hematol       Date:  2020-10-02       Impact factor: 3.673
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.